Takotsubo (stress) cardiomyopathy after ChAdOx1 nCoV-19 vaccination.
BMJ Case Rep
; 14(10)2021 Oct 08.
Article
in English
| MEDLINE | ID: covidwho-1462940
ABSTRACT
The global COVID-19 pandemic remains challenging with efforts for community vaccination the primary strategy to control transmission and disease sequalae in the mid to long term. While several candidate vaccines have been approved for use, there is an ongoing discussion regarding potential vaccine-related adverse events. Notably, thrombotic thrombocytopaenia has been reported following ChAdOx1 nCov-19 (AstraZeneca) vaccination. We report the first known case of takotsubo (stress) cardiomyopathy 4 days after administration of the ChAdOx1 nCoV-19 vaccine in a 72-year-old man. While this condition remains one primarily seen in females, our case represents a new trigger that warrants careful consideration when assessing patients presenting with acute coronary syndromes following ChAdOx1 nCoV-19 vaccination.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Cardiomyopathies
Type of study:
Case report
/
Observational study
Topics:
Vaccines
Limits:
Aged
/
Female
/
Humans
/
Male
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
Bcr-2021-246580
Similar
MEDLINE
...
LILACS
LIS